Leveraging its solid technological foundation and regulatory submission capabilities, Medgen has achieved market access breakthroughs for multiple core products. Its injectable artificial bone and oral bone graft substitutes have obtained Class III medical device registration certificates from the National Medical Products Administration in China, as well as Class D certification in Vietnam.

Johnson & Johnson reported Q1 2026 revenue of $24.06 billion, up 9.91% year-over-year, surpassing expectations and prompting an upward revision of full-year guidance. Leerink Partners upgraded J&J to 'Outperform' with a target price raised to $265, citing a robust pipeline of four blockbuster drugs, including an oral therapy projected to reach $10.5 billion in annual sales by 2032. On May 21, 2026, J&J announced that its FcRn antagonist Nicarlimab (An Li Wei) received NMPA approval in China for generalized Myasthenia Gravis, marking the first imported biologic under a domestic segmented production pilot program.

Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd. showcased its proprietary Wenno® Gingival Repair Membrane at the inaugural ADA Forsyth Dentech Asia 2026 in Seoul, marking its second appearance at an ADA Forsyth event following a 2025 collaboration agreement. Now backed by U.S. FDA clearance and NMPA registration, Wenno® offers equivalent keratinized gingiva widening to the gold-standard Free Gingival Graft—without requiring autologous tissue—while improving procedural efficiency, patient comfort, and aesthetics. The company’s booth attracted global dental leaders, signaling Neo Modulus’s strategic shift from a Chinese innovator to a global player in regenerative dentistry.

Johnson & Johnson received NMPA approval for nipocalimab (Anliwei®), a fully human FcRn antagonist, for generalized myasthenia gravis in combination with standard therapy. Separately, Kelun-Biotech announced that its TROP2-targeted antibody-drug conjugate sacituzumab tirumotecan (Sac-TMT) met the primary endpoint of progression-free survival (PFS) in the Phase III OptiTROP-Breast03 trial as first-line treatment for unresectable recurrent or metastatic triple-negative breast cancer (TNBC), marking the first domestic TROP2 ADC to achieve a positive Phase III result in this setting.

Shanghai Sanyou Medical Co., Ltd. (688085.SH) announced that its affiliated company Chunfeng Huayu's spine surgery robot system has completed the world's first registered clinical trial enrollment at Nanjing Drum Tower Hospital as of May 18, 2026. The system, which has passed China's NMPA Innovative Medical Device Special Review Program, successfully performed a complex spine surgery under full physician supervision with multi-modal navigation guidance. Featuring proprietary multi-arm collaborative technology, the robot represents a significant milestone in intelligent orthopedic surgery and paves the way for upcoming commercialization.

More than 30 years later, Beijing E-Town has grown into the core hub of Beijing's real economy. It features four major industrial clusters: new-generation information technology, high-end automobiles and new energy intelligent vehicles, biotech and big health, as well as robotics and intelligent manufacturing, with its total output value exceeding 600 billion RMB.

It should be noted that in invasive artificial hearts, higher flow support is not always better. Instead, multiple dimensions such as product size, support duration, and perfusion sealing technology need to be considered to provide tailored solutions for corresponding patients. For instance, the Impella series includes several models such as Impella CP, Impella 5.0, and Impella 2.5, offering different levels of maximum flow support at 3.7L/min, 5L/min, and 2.5L/min respectively, to meet the needs of different patients.

Star Sports Medicine, a Chinese medical device manufacturer, achieved significant overseas revenue growth in the late autumn of 2024, with the first three quarters exceeding 38 million yuan. Despite facing pricing pressures from volume-based procurement policies, Star Sports Medicine successfully launched China's first all-suture anchor by independently developing core technologies, addressing industry pain points associated with traditional metal implants. Since its establishment in 2017, the company has gradually risen in the sports medicine market, capturing a 6.5% market share to become the fourth-largest player in China. Driven by both technological innovation and market expansion, Star Sports Medicine has continuously broken the monopolies of international giants, emerging as a leader in China’s high-end medical device industry. In 2026, the company once again submitted its application for a Hong Kong IPO. Capital support and technological innovation have been key factors in its success.

On December 22, AstraZeneca's Benralizumab Injection (brand name: Fasenra®, generic name: Benralizumab Injection) received approval from the China National Medical Products Administration (NMPA) for a new indication, for the treatment of adult eosinophilic granulomatosis with polyangiitis (EGPA).

Hangzhou Yuanbao Biotechnology Co., Ltd. Completes Nearly RMB 100 Million Series A FinancingHangzhou Yuanbao Biotechnology Co., Ltd. has completed nearly RMB 100 million in Series A financing, led by Hotang Ventures with participation from Zhejiang Venture Capital and others; financial advisory information was not disclosed. Yuanbao Biotechnology is a clinical-application-oriented enterprise specializing in the research and development of musculoskeletal regenerative medical materials. It was jointly established by Professor Fan Shunwu's orthopedic team from Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, and the medical device industry. The proceeds from this round of financing will primarily be used to advance the clinical application of its core product, "Bone02 Bone Adhesive," which can rapidly bond in a blood-moist environment and achieve complete biodegradability. Additionally, the company’s representative products include a disposable gel patch former and porcine-derived bone repair materials. In the future, the bone adhesive is expected to be widely applied in various hard tissue bonding clinical scenarios.